欧州のバイオシミラー市場の2030年予測-適応疾患別、投与経路別、薬剤クラス別、流通チャネル別、地域別分析

欧州のバイオシミラー市場は、2022年の103億4,486万米ドルから2030年には1,151億2,591万米ドルに成長すると予測され、2022年から2030年までのCAGRは35.1%と推定されます。

当レポートでは、市場の動向と市場成長を促進する要因について取り上げています。市場成長の要因は、慢性疾患の有病率の増加とバイオシミラー医薬品の承認件数の増加です。さらに、バイオシミラーと臨床試験のための共同研究は、予測期間中、市場の重要な動向として浮上する可能性が高いです。しかし、バイオシミラー製品の製造における高コストの関与と複雑さが、予測期間2022～2030年の市場成長の妨げとなっています。

バイオシミラーと臨床試験のための共同事業が欧州のバイオシミラー市場を牽引

合弁事業やその他の提携モデルは、今後数年間、バイオシミラー医薬品メーカーが市場でライバルに対する競争力を維持するのに役立つと思われます。

バイオシミラー医薬品の研究、上市、販売を計画している他の企業と協力することで、バイオシミラー医薬品メーカーは製品を迅速に開発し、特許リスクを克服して臨床医や患者の信頼を得る形で効果的に上市することができます。製品開発は、国内外の専門知識、開発プラットフォームへのアクセス、研究・臨床試験資金を得ることで迅速化することができます。

大手バイオ医薬品メーカーと提携することで、確立された製造施設を利用することができます。共同研究は、細胞株開発、生物製剤やバイオシミラー医薬品の製造、プロセスのスケーリング、必要な技術移転などの業務をアウトソーシングするために行うことができます。

協業には長期的なメリットもあります。将来のバイオシミラー製造プロジェクトの国内入札を容易にし、早期かつ効率的な製品開発と市場開拓を可能にします。ヘルスケア政策や市場力学が国レベルで大きく異なる欧州のような巨大市場においては、このような協力関係を通じて得られる現地の知識へのアクセスも貴重なものとなります。

バイオシミラー市場の大きな可能性により、最近、多くの注目される共同研究が行われました。以下にその例をいくつか挙げる：

2023年6月、サムスン・バイオロジクスはファイザーとの戦略的提携を発表し、ファイザーの複数製品ポートフォリオの長期的な商業的製造を行うことになっています。この契約は、サムスン・バイオロジクスがファイザー社に、がん、炎症、免疫の各分野を網羅する多品目のバイオシミラー医薬品の大規模製造能力を提供することを目的としています。

2023年5月、ノバルティスの一部門であるサンドは、エボテック・バイオロジクスとのバイオシミラー共同開発を発表しました。この契約は、迅速な開発を目的とした複数のバイオシミラー医薬品の開発とその後の製造を対象としています。Evotec Biologics社の施設におけるバイオシミラー医薬品の開発は、今後12～18ヵ月で本格化する予定です。

このように、バイオシミラー製造と臨床試験のためのメーカーの提携は、予測期間中、バイオシミラー市場の主要動向となると思われます。

ブロックバスター生物製剤の特許失効が有利な市場機会を提供

生物学的製剤は、これまで不治の病であった疾患に対する有望な新治療法であり、医薬品市場において非常に重要な存在となっています。しかし、オリジネーターである生物学的製剤の特許は今後数年で失効すると予想されます。

売れ筋の生物学的製剤の特許および独占権の満了予定日は以下の表の通りです。

生物学的製剤

アバスチン2022年1月

サイラムザ 2023年5月

アドセトリス 2023年8月

アブスラックス 2024年10月

ガジーバ／ガジーバロ2024年11月

ダルザレックス 2026年5月

オクレバス 2027年4月

エムギャリティ 2028年9月

ヘムリブラ2028年2月

ルルメトリ2028年3月

イムフィンジ 2028年9月

マイロターグ 2028年4月

イムフィンジ 2028年9月

マイロタルグ 2028年4月

シルヴァント 2034年7月

出典ジェネリック医薬品・バイオシミラー・イニシアティブ（GaBI）ジャーナル

先発生物学的製剤の特許切れやその他の知的財産権により、将来的には新たなバイオシミラーの導入が必要となります。その結果、市場競争は今後数年間、業界内で激化すると思われます。このように、ブロックバスター生物製剤の特許失効は、予測期間中にバイオシミラー市場に有利な機会をもたらすと予想されます。

2022～2030年の欧州のバイオシミラー市場はドイツが最大シェアを占める。バイオシミラーは競合を導入し、生物製剤の購入しやすさを向上させ、最終的には節約と付加価値サービスを提供し、患者の治療とヘルスケアコミュニティを支援します。ヘルスケア専門家は、支出を削減しながら、より多くの患者を高品質の生物製剤で治療することができます。例えば、サンド社によると、ドイツでは、2022年にバイオシミラーが導入された後、抗TNF薬の1日治療用量が29％増加した（1,718万から2,218万へ）。

ドイツでは、バイオシミラーが適切な医薬品使用の不可欠な一部として、支払者、医療提供者、患者に受け入れられています。バイオシミラーへの即時の患者アクセスを含め、企業が設定した価格からの完全な償還があります。ドイツでは、複数の購買グループと別々の病院チェーンによる病院入札の構造により、メーカー間の競争が維持されています。例えば、2018年11月、ドイツ保健省は医薬品供給における安全性に関する法案を提出しました。Gesetz fur Mehr Sicherheit in der Arzneimittelversor-gung（GSAV）法案は、ドイツで薬剤師がバイオシミラーの自動代替を行うための法的枠組みを提供することを目的としています。

コスト削減の可能性が大きいことから、ドイツ保健省はバイオシミラーの採用を増やすために新法を導入しました。バイオシミラーの薬剤師による代替を認めている欧州連合（EU）諸国はほとんどないため、これは特にドイツにとって、実務の大きな変化を意味します。さらにドイツでは、2019年に可決された法律により、連邦合同委員会（医療保険者と医療提供者の自治の最高意思決定機関）が当該医薬品の互換性を判断し、処方医が明確に除外していない場合に限り、2022年から薬局でバイオシミラーが自動的に代替されることが予見されています。そのため、ドイツではバイオシミラーの採用に向けた政府の取り組みが活発化しており、市場の成長が見込まれています。

欧州のバイオシミラー市場では、さまざまな有機的・無機的戦略が企業によって採用されています。有機的戦略には主に、製品上市と製品承認が含まれます。さらに、市場で見られる無機的な成長戦略には、買収、提携、パートナーシップなどがあります。これらの成長戦略により、市場参入企業は事業を拡大し、地理的プレゼンスを高めることができ、それによって市場全体の成長に貢献します。さらに、買収と提携戦略は、市場参入企業が顧客基盤を強化し、製品ポートフォリオを拡大するのに役立ちます。欧州のバイオシミラー市場における主要企業の重要な発展の一部を以下に示します。

国際糖尿病連合、欧州医薬品庁、疾病管理予防センター、中国臨床腫瘍学、全国包括ケアネットワークは、欧州のバイオシミラー市場に関する報告書を作成する際に参照した主な一次情報および二次情報の一部です。

目次

第1章 イントロダクション

第2章 欧州のバイオシミラー市場-主要な要点

第3章 調査手法

• 調査範囲
• 2次調査
• 1次調査

第4章 欧州のバイオシミラー市場- 市場情勢

• 概要
  • 欧州PEST分析
• 実際の市場価格/正味価格
  • フランス
  • ドイツ
  • イタリア
  • スペイン
  • 英国

第5章 欧州のバイオシミラー市場

• 市場促進要因
  • 慢性疾患の有病率の増加
  • バイオシミラーの承認増加
• 市場抑制要因
  • バイオシミラー製品製造における高コストと複雑さ
• 市場機会
  • ブロックバスター生物製剤の特許切れ
• 今後の動向
  • バイオシミラーと臨床試験のためのコラボレーション
• 影響分析

第6章 欧州のバイオシミラー市場- 地域分析

• 欧州のバイオシミラー市場の収益予測と分析

第7章 欧州のバイオシミラー市場の2028年までの分析と予測：適応疾患別

• 概要
• 欧州のバイオシミラー市場、2022年・2030年、適応疾患別、売上高シェア（%）
• がん
• 糖尿病
• 自己免疫疾患
• その他の疾患

第8章 欧州のバイオシミラー市場の2028年までの分析と予測：投与経路別

• 概要
• 欧州のバイオシミラー市場、2022年・2030年、投与経路別、売上高シェア（%）
• 静脈内投与
• 皮下投与
• その他

第9章 欧州のバイオシミラー市場：2030年までの収益と予測：薬剤クラス別

• 概要
• 欧州のバイオシミラー市場、2022年・2030年、薬剤クラス別、売上高シェア（%）
• 顆粒球コロニー刺激因子
• インスリン
• TNF遮断薬およびモノクローナル抗体
• その他

第10章 欧州のバイオシミラー市場：2030年までの収益と予測：流通チャネル別

• 概要
• 欧州のバイオシミラー市場、2022年・2030年、流通チャネル別、売上高シェア（%）
• 内分泌専門医
• 免疫学者
• リウマチ専門医
• がん専門医
• 皮膚科医
• 網膜の調合
• その他
• 病院薬局
• 調剤薬局
• 小売薬局
• オンライン薬局

第11章 欧州のバイオシミラー市場、2030年までの収益と予測- 地域分析

第12章 COVID-19前後の影響

• COVID-19前後の影響

第13章 バイオシミラー市場- 業界情勢

• バイオシミラー市場の成長戦略
• 無機的成長戦略
• 有機的成長戦略

第14章 企業プロファイル

• Amgen Inc
• Celltrion Inc
• Sanofi SA
• Biocon Ltd
• Samsung Bioepis Co Ltd
• Eli Lilly and Co
• Sandoz AG
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc
• Dr. Reddy's Laboratories Ltd

第15章 付録

List Of Tables

• Table 1. Comparison Between Different Drug Developments
• Table 2. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
• Table 3. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
• Table 4. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
• Table 5. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
• Table 6. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
• Table 7. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
• Table 8. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
• Table 9. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
• Table 10. Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
• Table 11. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
• Table 12. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
• Table 13. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
• Table 14. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
• Table 15. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
• Table 16. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
• Table 17. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
• Table 18. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
• Table 19. Germany Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
• Table 20. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
• Table 21. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
• Table 22. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
• Table 23. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
• Table 24. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
• Table 25. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
• Table 26. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
• Table 27. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
• Table 28. UK Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
• Table 29. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
• Table 30. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
• Table 31. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
• Table 32. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
• Table 33. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
• Table 34. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
• Table 35. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
• Table 36. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
• Table 37. France Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
• Table 38. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
• Table 39. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
• Table 40. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
• Table 41. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
• Table 42. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
• Table 43. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
• Table 44. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
• Table 45. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
• Table 46. Italy Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
• Table 47. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
• Table 48. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
• Table 49. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
• Table 50. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
• Table 51. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
• Table 52. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
• Table 53. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
• Table 54. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
• Table 55. Spain Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
• Table 56. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Disease Indication
• Table 57. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn) - Autoimmune Diseases
• Table 58. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Route of Administration
• Table 59. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Drug Class
• Table 60. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Distribution Channel
• Table 61. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Hospital Pharmacies
• Table 62. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Compounding Pharmacies
• Table 63. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Retail Pharmacies
• Table 64. Rest of Europe Biosimilars Market Revenue And Forecast To 2030 (US$ Mn) - Online Pharmacies
• Table 65. Recent Inorganic Growth Strategies in the Biosimilars Market
• Table 66. Recent Organic Growth Strategies in Biosimilars Market
• Table 67. Glossary of Terms

List Of Figures

• Figure 1. Biosimilars Market Segmentation
• Figure 2. Biosimilars Market, by Region
• Figure 3. Key Insights
• Figure 4. Europe: PEST Analysis
• Figure 5. Europe Biosimilars Market- Key Industry Dynamics
• Figure 6. Europe Biosimilars Market: Impact Analysis of Drivers and Restraints
• Figure 7. Europe Biosimilars Market - Revenue Forecast and Analysis - 2020-2030
• Figure 8. Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
• Figure 9. Cancer: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 10. Diabetes: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 11. Autoimmune Diseases: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 12. Psoriasis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 13. Arthritis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 14. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 15. Other Disease Indication: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 16. Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
• Figure 17. Intravenous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 18. Subcutaneous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 19. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 20. Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
• Figure 21. Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 22. Insulin: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 23. TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 24. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 25. Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• Figure 26. Hospital Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 27. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 28. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 29. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 30. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 31. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 32. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 33. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 34. Compounding Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 35. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 36. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 37. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 38. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 39. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 40. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 41. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 42. Retail Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 43. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 44. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 45. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 46. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 47. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 48. Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 49. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 50. Online Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 51. Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 52. Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 53. Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 54. Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 55. Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 56. Retina Compounding: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 57. Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• Figure 58. Europe Biosimilars Market, By Region, 2022 ($Mn)
• Figure 59. Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
• Figure 60. Europe Biosimilars Market, By Key Countries, 2022 And 2030 (%)
• Figure 61. Germany Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
• Figure 62. UK Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
• Figure 63. France Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
• Figure 64. Italy Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
• Figure 65. Spain Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
• Figure 66. Rest of Europe Biosimilars Market Revenue And Forecast to 2030 (US$ Mn)
• Figure 67. Pre and Post COVID-19 Impact on Europe Biosimilars Market
• Figure 68. Growth Strategies in Biosimilars Market

The Europe biosimilars market is expected to grow from US$ 10,344.86 million in 2022 to US$ 1,15,125.91 million by 2030; it is estimated to grow at a CAGR of 35.1% from 2022 to 2030.

The report highlights trends prevailing in the market and factors driving the market growth. The market growth is attributed to the increasing prevalence of chronic diseases and rising approvals of biosimilars. Additionally, collaborations for biosimilars and clinical trials is likely to emerge as a significant trend in the market during the forecast period. However, high cost involvement and complexities in biosimilar product manufacturing hinders market growth during the forecast period 2022-2030.

Collaborations for Biosimilars and Clinical Trials Drives the Europe Biosimilars Market

Joint ventures and other collaboration models will help biosimilar medicine manufacturers maintain a competitive edge over rivals in the market in the coming years.

By collaborating with other companies planning to research, launch, and market biosimilar drugs, biosimilar manufacturers can develop their products rapidly and launch products effectively in a way that overcomes patent risks and gains clinician and patient confidence in the product. Product development can be expedited by gaining local and foreign expertise, development platform access, and research and clinical trial funding.

Collaborating with a bigger biopharmaceutical manufacturer allows access to established manufacturing facilities. The collaboration can be done for outsourcing activities such as cell line development, biologics and biosimilar manufacturing, process scaling, and any required technology transfer.

There are long-term benefits from collaborations. They can make it easy to tender for future biosimilar production projects within the country and offer early and efficient product development and market penetration. In a sizeable market such as Europe, which has significant country-level diversity in healthcare policies and market dynamics, access to local knowledge obtained through such collaborations can also prove invaluable.

The immense potential of the biosimilars market has led to many recent, high-profile collaborations. A few instances are given below:

In June 2023, Samsung Biologics announced a strategic partnership with Pfizer for the long-term commercial manufacturing of Pfizer's multi-product portfolio. The agreement aims that Samsung Biologics will offer Pfizer additional capacity for large-scale manufacturing of a multi-product biosimilar portfolio encompassing oncology, inflammation, and immunology.

In May 2023, Sandoz, a Novartis division, announced a biosimilar collaboration with Evotec Biologics. The agreement covers developing and manufacturing multiple biosimilar medicines intended for rapid development and the subsequent manufacturing of multiple biosimilars. The development of biosimilars at the Evotec Biologics facility will ramp up under the collaboration in the next 12-18 months.

Thus, collaborations of manufacturers for biosimilar production and clinical trials will be the key trend in the biosimilar market during the forecast period.

Patent Expiry of Blockbuster Biologics Offers Lucrative Market Opportunity

Biologicals represent promising new therapies for previously incurable diseases and are becoming highly important in the pharmaceuticals market. However, patents for originator biologicals are expected to expire in the coming years.

Estimated patent and exclusivity expiry dates for best-selling biologicals are given in the following table .

Biologicals Expiry Month & Years

Avastin January 2022

Cyramza May 2023

Adcetris August 2023

Abthrax October 2024

Gazyva/Gazyvaro November 2024

Darzalex May 2026

Ocrevus April 2027

Emgality September 2028

Hemlibra February 2028

Llumetri March 2028

Imfinzi September 2028

Mylotarg April 2028

Imfinzi September 2028

Mylotarg April 2028

Sylvant July 2034

Source: Generics and Biosimilars Initiative (GaBI) Journal

The patent expiration and other intellectual property rights for originator biologicals will create a need to introduce new biosimilars in the future. As a result, competition among market players will surge in the industry in the coming years. Thus, the patent expiry of blockbuster biologics is expected to create lucrative opportunities for the biosimilar market during the forecast period.

Germany holds largest market share for the Europe biosimilars market from 2022-2030. Biosimilars introduce competition and increase the affordability of biologics, which ultimately deliver savings and value-added services to support patient care and the healthcare community. Healthcare professionals can treat more patients with high-quality biologics while reducing spending. For example, in Germany, according to Sandoz, the number of daily therapeutic doses of an anti-TNF medicine increased by 29% (from 17.18 to 22.18 million) after introducing biosimilars in 2022.

Germany has achieved acceptance of biosimilars with payers, providers, and patients as an integral part of appropriate medicine use. There is full reimbursement from a price set by the company, including immediate patient access to biosimilars. The structure of hospital tendering by multiple buying groups and separate hospital chains allows for competition among manufacturers to be maintained in Germany. For instance, in November 2018, the German Health Ministry introduced a draft bill on safety in the supply of pharmaceuticals. The Gesetz fur Mehr Sicherheit in der Arzneimittelversor-gung (GSAV) bill aims to provide a legal framework for the automatic substitution of biosimilars by pharmacists in Germany.

Due to the huge potential for cost savings, the German Health Ministry introduced a new law to increase the adoption of biosimilars. As few European Union (EU) countries allow pharmacist substitution of biosimilars, this would represent a significant change in practice, particularly for Germany. Additionally, in Germany, a law passed in 2019 foresees the automatic substitution of biosimilars in pharmacies beginning in 2022, provided the Federal Joint Committee (the highest decision-making body of the self-governance of health insurers and providers) has determined the interchangeability of the medicines in question, and the prescribing physician has not explicitly excluded it. Therefore, with the growing government initiatives for adopting biosimilars in Germany, the market is expected to grow.

Various organic and inorganic strategies are adopted by companies in the Europe biosimilars market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players strengthen their customer base and expand their product portfolios. A few of the significant developments by key players in the Europe biosimilars market are listed below.

International Diabetes Federation, European Medicine Agency, Centers for Disease Control and Prevention, Chinese Clinical Oncology, National Comprehensive Care Network are a few of the major primary and secondary sources referred to while preparing the report on the Europe biosimilars market.

Reasons to Buy:

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe biosimilars market.
• Highlights key business priorities in order to assist companies to realign their business strategies.
• The key findings and recommendations highlight crucial progressive industry trends in the global Europe biosimilars market, thereby allowing players across the value chain to develop effective long-term strategies.
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
• Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
• Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Europe Biosimilars Market - Key Takeaways

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Europe Biosimilars Market - Market Landscape

• 4.1 Overview
  • 4.1.1 Europe PEST Analysis
• 4.2 Actual Market Price/Net Price
  • 4.2.1 France
  • 4.2.2 Germany
  • 4.2.3 Italy
  • 4.2.4 Spain
  • 4.2.5 UK

5. Europe Biosimilars Market

• 5.1 Market Drivers
  • 5.1.1 Increasing Prevalence of Chronic Diseases
  • 5.1.2 Rising Approvals of Biosimilars
• 5.2 Market Restraints
  • 5.2.1 High Cost Involvement and Complexities in Biosimilar Product Manufacturing
• 5.3 Market Opportunities
  • 5.3.1 Patent Expiry of Blockbuster Biologics
• 5.4 Future Trends
  • 5.4.1 Collaborations for Biosimilars and Clinical Trials
• 5.5 Impact analysis

6. Europe Biosimilars Market - Regional Analysis

• 6.1 Europe Biosimilars Market Revenue Forecast and Analysis

7. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Disease Indication

• 7.1 Overview
• 7.2 Europe Biosimilars Market Revenue Share, by Type 2022 & 2030 (%)
• 7.3 Cancer
  • 7.3.1 Overview
  • 7.3.2 Cancer: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 7.4 Diabetes
  • 7.4.1 Overview
  • 7.4.2 Diabetes: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 7.5 Autoimmune Diseases
  • 7.5.1 Overview
  • 7.5.2 Autoimmune Diseases: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5.3 Psoriasis
    • 7.5.3.1 Overview
  • 7.5.4 Psoriasis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5.5 Arthritis
    • 7.5.5.1 Overview
  • 7.5.6 Arthritis: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5.7 Others
    • 7.5.7.1 Overview
    • 7.5.7.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 7.6 Other Disease Indication
  • 7.6.1 Overview
  • 7.6.2 Other Disease Indication: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

8. Europe Biosimilars Market Analysis and Forecasts to 2028 - by Route of Administration

• 8.1 Overview
• 8.2 Europe Biosimilars Market, by Route of Administration 2022 & 2030 (%)
• 8.3 Intravenous
  • 8.3.1 Overview
  • 8.3.2 Intravenous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 8.4 Subcutaneous
  • 8.4.1 Overview
  • 8.4.2 Subcutaneous: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 8.5 Others
  • 8.5.1 Overview
  • 8.5.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

9. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Drug Class

• 9.1 Overview
• 9.2 Europe Biosimilars Market Revenue Share, by Drug Class 2022 & 2030 (%)
• 9.3 Granulocyte Colony-Stimulating Factor
  • 9.3.1 Overview
  • 9.3.2 Granulocyte Colony-Stimulating Factor: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 9.4 Insulin
  • 9.4.1 Overview
  • 9.4.2 Insulin: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 9.5 TNF Blockers and Monoclonal Antibodies
  • 9.5.1 Overview
  • 9.5.2 TNF Blockers and Monoclonal Antibodies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 9.6 Others
  • 9.6.1 Overview
  • 9.6.2 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

10. Europe Biosimilars Market - Revenue and Forecast to 2030 - by Distribution Channel

• 10.1 Overview
• 10.2 Europe Biosimilars Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
• 10.3 Endocrinologists
  • 10.3.1 Overview
• 10.4 Immunologists
  • 10.4.1 Overview
• 10.5 Rheumatologists
  • 10.5.1 Overview
• 10.6 Oncologists
  • 10.6.1 Overview
• 10.7 Dermatologists
  • 10.7.1 Overview
• 10.8 Retina Compounding
  • 10.8.1 Overview
• 10.9 Others
  • 10.9.1 Overview
• 10.10 Hospital Pharmacies
  • 10.10.1 Overview
  • 10.10.2 Hospital Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.10.3 Endocrinologists
    • 10.10.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.10.4 Immunologists
    • 10.10.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.10.5 Rheumatologists
    • 10.10.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.10.6 Oncologists
    • 10.10.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.10.7 Dermatologists
    • 10.10.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.10.8 Retina Specialists
    • 10.10.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.10.9 Others
    • 10.10.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 10.11 Compounding Pharmacies
  • 10.11.1 Overview
  • 10.11.2 Compounding Pharmacies : Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.11.3 Endocrinologists
    • 10.11.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.11.4 Immunologists
    • 10.11.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.11.5 Rheumatologists
    • 10.11.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.11.6 Oncologists
    • 10.11.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.11.7 Dermatologists
    • 10.11.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.11.8 Retina Specialists
    • 10.11.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.11.9 Others
    • 10.11.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 10.12 Retail Pharmacies
  • 10.12.1 Overview
  • 10.12.2 Retail Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.12.3 Endocrinologists
    • 10.12.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.12.4 Immunologists
    • 10.12.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.12.5 Rheumatologists
    • 10.12.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.12.6 Oncologists
    • 10.12.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.12.7 Dermatologists
    • 10.12.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.12.8 Retina Specialists
    • 10.12.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.12.9 Others
    • 10.12.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
• 10.13 Online Pharmacies
  • 10.13.1 Overview
  • 10.13.2 Online Pharmacies: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.13.3 Endocrinologists
    • 10.13.3.1 Endocrinologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.13.4 Immunologists
    • 10.13.4.1 Immunologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.13.5 Rheumatologists
    • 10.13.5.1 Rheumatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.13.6 Oncologists
    • 10.13.6.1 Oncologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.13.7 Dermatologists
    • 10.13.7.1 Dermatologists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.13.8 Retina Specialists
    • 10.13.8.1 Retina Specialists: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.13.9 Others
    • 10.13.9.1 Others: Europe Biosimilars Market - Revenue and Forecast to 2030 (US$ Million)

11. Europe Biosimilars Market - Revenue and Forecast to 2030 - Geographic Analysis

• 11.1 Europe Biosimilars Market, Revenue and Forecast to 2030
  • 11.1.1 Overview
  • 11.1.2 Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
    • 11.1.2.1 Europe Biosimilars Market, by Disease Indication
    • 11.1.2.2 Europe Biosimilars Market, by Autoimmune Diseases
    • 11.1.2.3 Europe Biosimilars Market, by Route of Administration
    • 11.1.2.4 Europe Biosimilars Market, by Drug Class
    • 11.1.2.5 Europe Biosimilars Market, by Distribution Channel
    • 11.1.2.6 Europe Biosimilars Market, by Hospital Pharmacies
    • 11.1.2.7 Europe Biosimilars Market, by Compounding Pharmacies
    • 11.1.2.8 Europe Biosimilars Market, by Retail Pharmacies
    • 11.1.2.9 Europe Biosimilars Market, by Online Pharmacies
    • 11.1.2.10 Europe Biosimilars Market by Country
      • 11.1.2.10.1 Germany
      • 11.1.2.10.1.1 Overview
      • 11.1.2.10.1.2 Germany Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.2.10.1.2.1 Germany Biosimilars Market, by Disease Indication
      • 11.1.2.10.1.2.2 Germany Biosimilars Market, by Autoimmune Diseases
      • 11.1.2.10.1.2.3 Germany Biosimilars Market, by Route of Administration
      • 11.1.2.10.1.2.4 Germany Biosimilars Market, by Drug Class
      • 11.1.2.10.1.2.5 Germany Biosimilars Market, by Distribution Channel
      • 11.1.2.10.1.2.6 Germany Biosimilars Market, by Hospital Pharmacies
      • 11.1.2.10.1.2.7 Germany Biosimilars Market, by Compounding Pharmacies
      • 11.1.2.10.1.2.8 Germany Biosimilars Market, by Retail Pharmacies
      • 11.1.2.10.1.2.9 Germany Biosimilars Market, by Online Pharmacies
      • 11.1.2.10.2 UK
      • 11.1.2.10.3 Overview
      • 11.1.2.10.3.1 UK Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.2.10.3.1.1 UK Biosimilars Market, by Disease Indication
      • 11.1.2.10.3.1.2 UK Biosimilars Market, by Autoimmune Diseases
      • 11.1.2.10.3.1.3 UK Biosimilars Market, by Route of Administration
      • 11.1.2.10.3.1.4 UK Biosimilars Market, by Drug Class
      • 11.1.2.10.3.1.5 UK Biosimilars Market, by Distribution Channel
      • 11.1.2.10.3.1.6 UK Biosimilars Market, by Hospital Pharmacies
      • 11.1.2.10.3.1.7 UK Biosimilars Market, by Compounding Pharmacies
      • 11.1.2.10.3.1.8 UK Biosimilars Market, by Retail Pharmacies
      • 11.1.2.10.3.1.9 UK Biosimilars Market, by Online Pharmacies
      • 11.1.2.10.4 France
      • 11.1.2.10.4.1 Overview
      • 11.1.2.10.4.2 France Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.2.10.4.2.1 France Biosimilars Market, by Disease Indication
      • 11.1.2.10.4.2.2 France Biosimilars Market, by Autoimmune Diseases
      • 11.1.2.10.4.2.3 France Biosimilars Market, by Route of Administration
      • 11.1.2.10.4.2.4 France Biosimilars Market, by Drug Class
      • 11.1.2.10.4.2.5 France Biosimilars Market, by Distribution Channel
      • 11.1.2.10.4.2.6 France Biosimilars Market, by Hospital Pharmacies
      • 11.1.2.10.4.2.7 France Biosimilars Market, by Compounding Pharmacies
      • 11.1.2.10.4.2.8 France Biosimilars Market, by Retail Pharmacies
      • 11.1.2.10.4.2.9 France Biosimilars Market, by Online Pharmacies
      • 11.1.2.10.5 Italy
      • 11.1.2.10.5.1 Overview
      • 11.1.2.10.5.2 Italy Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.2.10.5.2.1 Italy Biosimilars Market, by Disease Indication
      • 11.1.2.10.5.2.2 Italy Biosimilars Market, by Autoimmune Diseases
      • 11.1.2.10.5.2.3 Italy Biosimilars Market, by Route of Administration
      • 11.1.2.10.5.2.4 Italy Biosimilars Market, by Drug Class
      • 11.1.2.10.5.2.5 Italy Biosimilars Market, by Distribution Channel
      • 11.1.2.10.5.2.6 Italy Biosimilars Market, by Hospital Pharmacies
      • 11.1.2.10.5.2.7 Italy Biosimilars Market, by Compounding Pharmacies
      • 11.1.2.10.5.2.8 Italy Biosimilars Market, by Retail Pharmacies
      • 11.1.2.10.5.2.9 Italy Biosimilars Market, by Online Pharmacies
      • 11.1.2.10.6 Spain
      • 11.1.2.10.6.1 Overview
      • 11.1.2.10.6.2 Spain Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.2.10.6.2.1 Spain Biosimilars Market, by Disease Indication
      • 11.1.2.10.6.2.2 Spain Biosimilars Market, by Autoimmune Diseases
      • 11.1.2.10.6.2.3 Spain Biosimilars Market, by Route of Administration
      • 11.1.2.10.6.2.4 Spain Biosimilars Market, by Drug Class
      • 11.1.2.10.6.2.5 Spain Biosimilars Market, by Distribution Channel
      • 11.1.2.10.6.2.6 Spain Biosimilars Market, by Hospital Pharmacies
      • 11.1.2.10.6.2.7 Spain Biosimilars Market, by Compounding Pharmacies
      • 11.1.2.10.6.2.8 Spain Biosimilars Market, by Retail Pharmacies
      • 11.1.2.10.6.2.9 Spain Biosimilars Market, by Online Pharmacies
      • 11.1.2.10.7 Rest of Europe
      • 11.1.2.10.7.1 Overview
      • 11.1.2.10.7.2 Rest of Europe Biosimilars Market Revenue and Forecast to 2030 (US$ Mn)
      • 11.1.2.10.7.2.1 Rest of Europe Biosimilars Market, by Disease Indication
      • 11.1.2.10.7.2.2 Rest of Europe Biosimilars Market, by Autoimmune Diseases
      • 11.1.2.10.7.2.3 Rest of Europe Biosimilars Market, by Route of Administration
      • 11.1.2.10.7.2.4 Rest of Europe Biosimilars Market, by Drug Class
      • 11.1.2.10.7.2.5 Rest of Europe Biosimilars Market, by Distribution Channel
      • 11.1.2.10.7.2.6 Rest of Europe Biosimilars Market, by Hospital Pharmacies
      • 11.1.2.10.7.2.7 Rest of Europe Biosimilars Market, by Compounding Pharmacies
      • 11.1.2.10.7.2.8 Rest of Europe Biosimilars Market, by Retail Pharmacies
      • 11.1.2.10.7.2.9 Rest of Europe Biosimilars Market, by Online Pharmacies

12. Pre and Post COVID-19 Impact

• 12.1 Pre and Post COVID-19 Impact

13. Biosimilars Market - Industry Landscape

• 13.1 Overview
• 13.2 Growth Strategies in Biosimilars Market
• 13.3 Inorganic Growth Strategies
  • 13.3.1 Overview
• 13.4 Organic Growth Strategies
  • 13.4.1 Overview

14. Company Profiles

• 14.1 Amgen Inc
  • 14.1.1 Key Facts
  • 14.1.2 Business Description
  • 14.1.3 Products and Services
  • 14.1.4 Financial Overview
  • 14.1.5 SWOT Analysis
  • 14.1.6 Key Developments
• 14.2 Celltrion Inc
  • 14.2.1 Key Facts
  • 14.2.2 Business Description
  • 14.2.3 Products and Services
  • 14.2.4 Financial Overview
  • 14.2.5 SWOT Analysis
  • 14.2.6 Key Developments
• 14.3 Sanofi SA
  • 14.3.1 Key Facts
  • 14.3.2 Business Description
  • 14.3.3 Products and Services
  • 14.3.4 Financial Overview
  • 14.3.5 SWOT Analysis
• 14.4 Biocon Ltd
  • 14.4.1 Key Facts
  • 14.4.2 Business Description
  • 14.4.3 Products and Services
  • 14.4.4 Financial Overview
  • 14.4.5 SWOT Analysis
  • 14.4.6 Key Developments
• 14.5 Samsung Bioepis Co Ltd
  • 14.5.1 Key Facts
  • 14.5.2 Business Description
  • 14.5.3 Products and Services
  • 14.5.4 Financial Overview
  • 14.5.5 SWOT Analysis
  • 14.5.6 Key Developments
• 14.6 Eli Lilly and Co
  • 14.6.1 Key Facts
  • 14.6.2 Business Description
  • 14.6.3 Products and Services
  • 14.6.4 Financial Overview
  • 14.6.5 SWOT Analysis
  • 14.6.6 Key Developments
• 14.7 Sandoz AG
  • 14.7.1 Key Facts
  • 14.7.2 Business Description
  • 14.7.3 Products and Services
  • 14.7.4 Financial Overview
  • 14.7.5 SWOT Analysis
  • 14.7.6 Key Developments
• 14.8 Teva Pharmaceutical Industries Ltd
  • 14.8.1 Key Facts
  • 14.8.2 Business Description
  • 14.8.3 Products and Services
  • 14.8.4 Financial Overview
  • 14.8.5 SWOT Analysis
  • 14.8.6 Key Developments
• 14.9 Pfizer Inc
  • 14.9.1 Key Facts
  • 14.9.2 Business Description
  • 14.9.3 Products and Services
  • 14.9.4 Financial Overview
  • 14.9.5 SWOT Analysis
  • 14.9.6 Key Developments
• 14.10 Dr. Reddy's Laboratories Ltd
  • 14.10.1 Key Facts
  • 14.10.2 Business Description
  • 14.10.3 Products and Services
  • 14.10.4 Financial Overview
  • 14.10.5 SWOT Analysis
  • 14.10.6 Key Developments

15. Appendix

• 15.1 About The Insight Partners
• 15.2 Glossary of Terms